The trial has been registered with the FDA: http://clinicaltrials.gov/ct2/show/NCT02032004
The primary outcome is: Time to first heart failure (HF)-related major adverse cardiac events (HF-MACE) [ Time Frame: 5 Years ] [ Designated as safety issue: No ]
Can anybody explain how the trial could be finished in 2018 with a 5 year time frame for the primary measure?
I note that there are a number of secondary measures that are assessed at interim periods [ Time Frame: Baseline, months 3, 6, 12, 24, 36, 48, and 60 ] so I expect there will be regular interim analyses which should keep us salivating.
The trial has been registered with the FDA:...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |